252 related articles for article (PubMed ID: 32035635)
1. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
[TBL] [Abstract][Full Text] [Related]
2. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
[TBL] [Abstract][Full Text] [Related]
3. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
[TBL] [Abstract][Full Text] [Related]
4. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
[TBL] [Abstract][Full Text] [Related]
5. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
9. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
10. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
Fitzgerald DA; Doumit M; Abel F
Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
[TBL] [Abstract][Full Text] [Related]
11. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
[TBL] [Abstract][Full Text] [Related]
12. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
[TBL] [Abstract][Full Text] [Related]
13. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
[TBL] [Abstract][Full Text] [Related]
14. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
15. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
17. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
[No Abstract] [Full Text] [Related]
18. Nusinersen treatment of spinal muscular atrophy - a systematic review.
Albrechtsen SS; Born AP; Boesen MS
Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
[TBL] [Abstract][Full Text] [Related]
19. Natural History of Type 1 Spinal Muscular Atrophy in a Series of Argentinian Children.
Aguerre V; De Castro F; Mozzoni J; Gravina LP; Araoz HV; Monges S
J Neuromuscul Dis; 2020; 7(4):453-458. PubMed ID: 32925085
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
